22,99 €
inkl. MwSt.

Versandfertig in über 4 Wochen
  • Broschiertes Buch

The discovery of imidazoline binding sites has broadened the horizon of drug development for the treatment of physiological and psychological conditions. The pharmacology of these sites has been extensively researched over the past few years. However, one of the puzzling questions that remains uncertain is the identity of an endogenous ligand for these binding sites. The beta-carboline harmane has been identified as the bioactive constituent of clonidine-displacing substance. The objective of this work was to investigate the neurotransmitter properties of harmane examining its uptake and…mehr

Produktbeschreibung
The discovery of imidazoline binding sites has broadened the horizon of drug development for the treatment of physiological and psychological conditions. The pharmacology of these sites has been extensively researched over the past few years. However, one of the puzzling questions that remains uncertain is the identity of an endogenous ligand for these binding sites. The beta-carboline harmane has been identified as the bioactive constituent of clonidine-displacing substance. The objective of this work was to investigate the neurotransmitter properties of harmane examining its uptake and release in rat brain to determine whether it resembles that of a classical neurotransmitter. Further analyses, assessed the role of harmane on monoamine release in rat brain, illustrating its specificity on serotonin release in rat brain. Although harmane may not fulfill the criteria as a typical neurotransmitter, its specific mode of action on the serotonergic system may aid in the treatment of mood disorders.
Autorenporträt
La Dra. Haya Abu Ghazaleh es licenciada y doctora en Farmacología y tiene una maestría en Investigación Clínica. Sus intereses de investigación incluyen los patrones de adicción a la comida en Oriente Medio y el comportamiento de los fumadores en personas con enfermedades crónicas. En la actualidad es profesora del King's College de Londres (Reino Unido) y sigue apoyando la investigación en el grupo de diabetes.